How much revenue does Jubilant Pharmova make?

Jubilant Pharmova reported 71.92 billion INR in revenue for fiscal year 2025, up 8.2% from 66.45 billion INR in fiscal year 2024. In Q1 2026 revenue was 18.79 billion INR.

What is Jubilant Pharmova's largest business segment?

Radio Pharma, with 33.88 billion INR or 46% of segment revenue in fiscal year 2025. Next: Contract Development and Manufacturing Organization - Sterile Injectables (18%) and Contract Research, Development and Manufacturing Organization (16%).

Where does Jubilant Pharmova make most of its revenue?

Americas and Europe: 91% of revenue by region in fiscal year 2025, followed by Rest of The World (6%).

What companies are similar to Jubilant Pharmova?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Pfizer Limited (PFIZER.NS), Eris Lifesciences Limited (ERIS.NS), Alembic Pharmaceuticals Limited (APLLTD.BO), Natco Pharma Limited (NATCOPHARM.NS).

Jubilant Pharmova Limited (JUBLPHARMA.NS) Stock

About Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment of...

At a glance

Jubilant Pharmova reported revenue of 71.92 billion INR for fiscal year 2025, up 8.2% from fiscal year 2024, and net income of 8.39 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 18.79 billion INR, up 9.2% from a year before. Its largest business segment, Radio Pharma, brought in 46% of segment revenue in fiscal year 2025; Americas and Europe was the largest region with 91%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.